home / stock / pdsb / pdsb news

PDSB News and Press, PDS Biotechnology Corporation From 05/18/23

Stock Information
Company Name: PDS Biotechnology Corporation
Stock Symbol: PDSB
Market: NASDAQ
Website: pdsbiotech.com
Menu
PDSB PDSB Quote PDSB Short PDSB News PDSB Articles PDSB Message Board
Get PDSB Alerts

News, Short Squeeze, Breakout and More Instantly...
PDSB - PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the immune che...
PDSB - PDS Biotechnology Corporation (PDSB) Q1 2023 Earnings Call Transcript

2023-05-15 10:33:10 ET PDS Biotechnology Corporation (PDSB) Q1 2023 Earnings Conference Call May 15, 2023, 08:00 AM ET Company Participants Gabby DeGravina - Investor Relations Frank Bedu-Addo - Chief Executive Officer Matt Hill - Chief Financial Officer Laur...

PDSB - PDS Biotechnology GAAP EPS of -$0.32 misses by $0.01

2023-05-15 07:36:35 ET PDS Biotechnology press release ( NASDAQ: PDSB ): Q1 GAAP EPS of -$0.32 misses by $0.01 . Cash and cash equivalents as of March 31, 2023, totaled approximately $65.2 million. Based on the Company’s cash resources with the anticipated initi...

PDSB - PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage com...
PDSB - PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results fo...

PDSB - PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

FLORHAM PARK, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the presentation of updated data from the VERSATILE-00...

PDSB - PDS Biotechnology: Late-Stage Biotech With Enormous Potential

2023-04-26 13:15:56 ET Summary Initiation of phase 3 study using PDS0101 in combination with Keytruda for the treatment of patients with unresectable, recurrent/metastatic Human Papillomavirus positive head and neck cancer expected Q4 of 2023. It is said that the global head and n...
PDSB - PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

FLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease announced the Company received $1.4 million from the net sale...

PDSB - PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced it will host a Key Opinion Leader (KOL) Roundtable on ...

PDSB - PDS Biotechnology's PDS0101 Shows Potential In HPV-Positive Head And Neck Cancers

2023-04-05 06:57:49 ET Summary PDS0101, an innovative immunotherapy, targets HPV-positive cancers, including recurrent or metastatic head and neck cancer with high-risk HPV16 infection. VERSATILE-002 Phase 2 clinical trial demonstrates improved efficacy and a favorable safety prof...
Previous 10 Next 10